Lipid C2 |
| Catalog No.GC91633 |
Lipid C2 is an ionizable cationic lipid that has been used in the formation of lipid nanoparticles (LNPs) for mRNA delivery in vivo.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 3003022-09-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Lipid C2 is an ionizable cationic lipid that has been used in the formation of lipid nanoparticles (LNPs) for mRNA delivery in vivo.[1] LNPs containing lipid C2 and encapsulating an mRNA reporter selectively accumulate in the liver and spleen but not the heart, lungs, or kidneys in mice. LNPs containing lipid C2 and encapsulating mRNA encoding the Epstein-Barr virus (EBV) protein latent membrane protein 2 (LMP-2), in combination with an anti-programmed cell death protein 1 (PD-1) antibody, decrease tumor volume and reverse T cell exhaustion, as well as increase the percentage of CD3+CD8+ central and CD3+CD8+ effector memory T cells and decrease the percentage of CD3+ T cells expressing Pd-1, in the spleen in a CT26 murine EBV-infected colon cancer model.
References:
[1].Xiang, Y., Tian, M., Huang, J., et al.LMP2-mRNA lipid nanoparticle sensitizes EBV-related tumors to anti-PD-1 therapy by reversing T cell exhaustionJ. Nanobiotechnology21(1)324(2023).
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *